Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Adverse events associated with abemaciclib were characterised in patients participating in the phase III open-label monarchE study
Close monitoring needed to allow earlier identification and effective management of interstitial lung disease
Translational findings from the WSG-ADAPT study
Swedish investigators found that clinical benefit with endocrine therapy differs by risk group
No new safety signals occurred with neoadjuvant pertuzumab/trastuzumab at five years
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
